{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:46Z","timestamp":1756902166335,"version":"3.44.0"},"reference-count":137,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>Infantile hemangioma (IH) is the most prevalent benign vascular tumor among infants. While most hemangioma cases typically undergo spontaneous resolution, there is a risk of complications and concern over changes in appearance in certain circumstances. The treatment options include oral and topical drug therapy, laser therapy, and surgery. Because the lesions are (but not exclusively) formed on the skin\u2019s surface and exhibit features typical of tumors, there are opportunities for implementing nanoparticle technology for systemic and topical treatments. Nanotechnology in drug delivery generally aims to boost the efficacy of substance penetration or absorption, prevent systemic side effects by passive or active targeting, prolong effectiveness, and reduce the dose and duration of treatment. Several types of nanoparticles have been selected as research subjects in nanoparticle-based studies for treating IH. The type of nanoparticle is chosen based on evaluations of many factors, such as the active substance\u2019s physical and chemical compatibility, target site, and route of administration, and the formula is constructed by using an optimization process, resulting in a system with distinctive advantages<\/jats:p>","DOI":"10.5863\/1551-6776-30.1.27","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T14:25:25Z","timestamp":1745245525000},"page":"27-46","source":"Crossref","is-referenced-by-count":0,"title":["Nanotechnology in Infantile Hemangioma Management"],"prefix":"10.5863","volume":"30","author":[{"given":"Muhammad","family":"Sulaiman","sequence":"first","affiliation":[{"name":"Doctoral Program (MS), Faculty of Pharmacy, Department of Pharmaceutical Chemistry (EL, RM), Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia; Department of Dermatology and Venereology (YWW, RD), Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Endang","family":"Lukitaningsih","sequence":"additional","affiliation":[{"name":"Doctoral Program (MS), Faculty of Pharmacy, Department of Pharmaceutical Chemistry (EL, RM), Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia; Department of Dermatology and Venereology (YWW, RD), Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronny","family":"Martien","sequence":"additional","affiliation":[{"name":"Doctoral Program (MS), Faculty of Pharmacy, Department of Pharmaceutical Chemistry (EL, RM), Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia; Department of Dermatology and Venereology (YWW, RD), Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohanes Widodo","family":"Wirohadidjojo","sequence":"additional","affiliation":[{"name":"Doctoral Program (MS), Faculty of Pharmacy, Department of Pharmaceutical Chemistry (EL, RM), Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia; Department of Dermatology and Venereology (YWW, RD), Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Retno","family":"Danarti","sequence":"additional","affiliation":[{"name":"Doctoral Program (MS), Faculty of Pharmacy, Department of Pharmaceutical Chemistry (EL, RM), Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia; Department of Dermatology and Venereology (YWW, RD), Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"(3)","key":"i2331-348X-30-1-27-b01","series-title":"Saudi J Ophthalmol","first-page":"283","article-title":"Infantile hemangiomas: a review","volume":"26","author":"Callahan","year":"2012","unstructured":"Callahan AB, Yoon MK. Infantile hemangiomas: a review. Saudi J Ophthalmol. 2012;26(3):283\u2013291."},{"issue":"(12)","key":"i2331-348X-30-1-27-b02","series-title":"Arch Dermatol","first-page":"1567","article-title":"Hemangiomas of infancy","volume":"138","author":"Chiller","year":"2002","unstructured":"Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy. Arch Dermatol.  2002;138(12):1567\u20131576."},{"issue":"(6)","key":"i2331-348X-30-1-27-b03","series-title":"J Am Acad Dermatol","first-page":"1379","article-title":"Infantile hemangioma\u2014Part 1: epidemiology, pathogenesis, clinical presentation and assessment","volume":"85","author":"Rodr\u00edguez Bandera","year":"2021","unstructured":"Rodr\u00edguez Bandera AI, Sebaratnam DF, Wargon O, Wong LCF. Infantile hemangioma\u2014Part 1: epidemiology, pathogenesis, clinical presentation and assessment. J Am Acad Dermatol. 2021;85(6):1379\u20131392."},{"issue":"(6)","key":"i2331-348X-30-1-27-b04","series-title":"Pediatr Dermatol","first-page":"663","article-title":"A prospective study of infantile hemangiomas with a focus on incidence and risk factors","volume":"28","author":"Dickison","year":"2011","unstructured":"Dickison P, Christou E, Wargon O. A prospective study of infantile hemangiomas with a focus on incidence and risk factors. Pediatr Dermatol. 2011;28(6):663\u2013669."},{"issue":"(2)","key":"i2331-348X-30-1-27-b05","series-title":"J Am Acad Dermatol","first-page":"493","article-title":"Late growth of infantile hemangiomas in children >3 years of age: a retrospective study","volume":"80","author":"O\u2019Brien","year":"2019","unstructured":"O\u2019Brien KF, Shah SD, Pope E, et al. Late growth of infantile hemangiomas in children >3 years of age: a retrospective study. J Am Acad Dermatol. 2019;80(2):493\u2013499."},{"issue":"(1)","key":"i2331-348X-30-1-27-b06","series-title":"J Am Acad Dermatol","first-page":"120","article-title":"Increasing incidence of infantile hemangiomas (IH) over the past 35 years: correlation with decreasing gestational age at birth and birth weight","volume":"74","author":"Anderson","year":"2016","unstructured":"Anderson KR, Schoch JJ, Lohse CM, et al. Increasing incidence of infantile hemangiomas (IH) over the past 35 years: correlation with decreasing gestational age at birth and birth weight. J Am Acad Dermatol. 2016;74(1):120\u2013126."},{"issue":"(10089)","key":"i2331-348X-30-1-27-b07","series-title":"Lancet","first-page":"85","article-title":"Infantile haemangioma","volume":"390","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2017","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85\u201394."},{"issue":"(1)","key":"i2331-348X-30-1-27-b08","series-title":"Exp Ther Med","first-page":"307","article-title":"Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells","volume":"17","author":"Bota","year":"2019","unstructured":"Bota M, Fischer-Fodor E, Bochi\u0219 O, et al. Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells. Exp Ther Med.  2019;17(1):307\u2013315."},{"issue":"(1)","key":"i2331-348X-30-1-27-b09","series-title":"Otolaryngol Head Neck Surg","first-page":"182","article-title":"Airway hemangiomas in PHACE syndrome: a multicenter experience","volume":"165","author":"Czechowicz","year":"2021","unstructured":"Czechowicz JA, Benjamin T, Bly RA, et al. Airway hemangiomas in PHACE syndrome: a multicenter experience. Otolaryngol Head Neck Surg. 2021;165(1):182\u2013186."},{"issue":"(2)","key":"i2331-348X-30-1-27-b10","series-title":"Res Rep Neonatol","first-page":"55","article-title":"Infantile hemangiomas: from pathogenesis to clinical features","author":"Rosbe","year":"2012","unstructured":"Rosbe K. Infantile hemangiomas: from pathogenesis to clinical features. Res Rep Neonatol. 2012;(2):55\u201364."},{"issue":"(1)","key":"i2331-348X-30-1-27-b11","series-title":"Plast Reconstr Surg","first-page":"230","article-title":"Unilateral cleft lip repair in the presence of a vermilion hemangioma","volume":"99","author":"Williams","year":"1997","unstructured":"Williams JK, Hitncr JB, Wood RJ. Unilateral cleft lip repair in the presence of a vermilion hemangioma. Plast Reconstr Surg.  1997;99(1):230\u2013233."},{"key":"i2331-348X-30-1-27-b12","series-title":"Biomed Pharmacother","first-page":"1499","article-title":"Application of nanoparticles in percutaneous delivery of active ingredients in cosmetic preparations","volume":"106","author":"Khezri","year":"2018","unstructured":"Khezri K, Saeedi M, Maleki Dizaj S. Application of nanoparticles in percutaneous delivery of active ingredients in cosmetic preparations. Biomed Pharmacother.  2018;(Oct:106):1499\u20131505."},{"key":"i2331-348X-30-1-27-b13","series-title":"J Drug Deliv Sci Technol","first-page":"104305","article-title":"Mesoporous silica nanoparticles: synthesis and multifaceted functionalization for controlled drug delivery","volume":"81","author":"Gupta","year":"2023","unstructured":"Gupta J, Quadros M, Momin M. Mesoporous silica nanoparticles: synthesis and multifaceted functionalization for controlled drug delivery. J Drug Deliv Sci Technol. 2023;(81):104305."},{"key":"i2331-348X-30-1-27-b14","series-title":"Front Oncol","first-page":"1","article-title":"Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas","volume":"8)","author":"Wu","year":"2018","unstructured":"Wu HW, Wang X, Zhang L, et al. Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas. Front Oncol. 2018;(8):1\u20136."},{"issue":"(10)","key":"i2331-348X-30-1-27-b15","series-title":"Acta Derm Venereol","first-page":"1167","article-title":"The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis","volume":"97","author":"Khan","year":"2017","unstructured":"Khan M, Boyce A, Prieto-Merino D, et al. The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis. Acta Derm Venereol. 2017;97(10):1167\u20131171."},{"issue":"(5)","key":"i2331-348X-30-1-27-b16","series-title":"J Stomatol Oral Maxillofac Surg","first-page":"e499","article-title":"Sandwich therapy in the management of propranolol resistant infantile hemangioma of the lip","volume":"123","author":"Tiwari","year":"2022","unstructured":"Tiwari P, Pandey V, Bera RN, et al. Sandwich therapy in the management of propranolol resistant infantile hemangioma of the lip. J Stomatol Oral Maxillofac Surg. 2022;123(5):e499\u2013e505."},{"issue":"(1)","key":"i2331-348X-30-1-27-b17","series-title":"Asian J Surg","first-page":"154","article-title":"Additive value of single intralesional bleomycin injection in the management of propranolol for proliferative infantile hemangioma","volume":"47","author":"Guo","year":"2023","unstructured":"Guo L, Wang M, Song D, et al. Additive value of single intralesional bleomycin injection in the management of propranolol for proliferative infantile hemangioma. Asian J Surg. 2023;47(1):154-157"},{"issue":"(3)","key":"i2331-348X-30-1-27-b18","series-title":"Pharm Res","first-page":"866","article-title":"Evaluation of skin permeation of \u03b2-blockers for topical drug delivery","volume":"30","author":"Chantasart","year":"2013","unstructured":"Chantasart D, Hao J, Li SK. Evaluation of skin permeation of \u03b2-blockers for topical drug delivery. Pharm Res. 2013;30(3):866\u2013877."},{"issue":"(3)","key":"i2331-348X-30-1-27-b19","series-title":"Acta Ophthalmol Scand","first-page":"294","article-title":"Capillary haemogioma of the eyelids and orbit: a clinical review of the safety and efficacy of intralesional steroid","volume":"81","author":"O\u2019Keefe","year":"2003","unstructured":"O\u2019Keefe M, Lanigan B, Byrne SA. Capillary haemogioma of the eyelids and orbit: a clinical review of the safety and efficacy of intralesional steroid. Acta Ophthalmol Scand. 2003;81(3):294\u2013298."},{"issue":"(11)","key":"i2331-348X-30-1-27-b20","series-title":"J Plast Reconstr Aesthetic Surg","first-page":"1469","article-title":"Management of problematic infantile hemangioma using intralesional triamcinolone: efficacy and safety in 100 infants","volume":"67","author":"Couto","year":"2014","unstructured":"Couto JA, Greene AK. Management of problematic infantile hemangioma using intralesional triamcinolone: efficacy and safety in 100 infants. J Plast Reconstr Aesthetic Surg. 2014;67(11):1469\u20131474."},{"issue":"(2)","key":"i2331-348X-30-1-27-b21","series-title":"Pediatr Dermatol","first-page":"156","article-title":"Failure of intralesional propranolol in infantile hemangiomas","volume":"31","author":"Torres-Pradilla","year":"2014","unstructured":"Torres-Pradilla M, Baselga E. Failure of intralesional propranolol in infantile hemangiomas. Pediatr Dermatol. 2014;31(2):156\u2013158."},{"issue":"(5)","key":"i2331-348X-30-1-27-b22","series-title":"Curr Drug Deliv","first-page":"444","article-title":"Topical and transdermal drug delivery: from simple potions to smart technologies","volume":"16","author":"Benson","year":"2019","unstructured":"Benson HAE, Grice JE, Mohammed Y, et al. Topical and transdermal drug delivery: from simple potions to smart technologies. Curr Drug Deliv. 2019;16(5):444\u2013460."},{"issue":"(2)","key":"i2331-348X-30-1-27-b23","series-title":"Chinese Chem Lett","first-page":"107518","article-title":"Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment","volume":"34","author":"Liu","year":"2023","unstructured":"Liu R, Luo C, Pang Z, et al. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chinese Chem Lett. 2023;34(2):107518."},{"issue":"(2)","key":"i2331-348X-30-1-27-b24","series-title":"Angiogenesis","first-page":"197","article-title":"Vasculogenesis in infantile hemangioma","volume":"12","author":"Boscolo","year":"2009","unstructured":"Boscolo E, Bischoff J. Vasculogenesis in infantile hemangioma. Angiogenesis. 2009;12(2):197\u2013207."},{"issue":"(22)","key":"i2331-348X-30-1-27-b25","series-title":"Ann Transl Med","first-page":"692","article-title":"Progress in the treatment of infantile hemangioma","volume":"7","author":"Chen","year":"2019","unstructured":"Chen Z-Y, Wang Q-N, Zhu Y-H, et al. Progress in the treatment of infantile hemangioma. Ann Transl Med.  2019;7(22):692."},{"issue":"(7)","key":"i2331-348X-30-1-27-b26","series-title":"Eur J Pediatr","first-page":"855","article-title":"Treatment of infantile haemangiomas: recommendations of a European expert group","volume":"174","author":"Hoeger","year":"2015","unstructured":"Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855\u2013865."},{"issue":"(6)","key":"i2331-348X-30-1-27-b27","series-title":"J Clin Invest","first-page":"745","article-title":"Clonality and altered behavior of endothelial cells from hemangiomas","volume":"107","author":"Boye","year":"2001","unstructured":"Boye E, Yu Y, Paranya G, et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest. 2001;107(6):745\u2013752."},{"issue":"(5)","key":"i2331-348X-30-1-27-b28","series-title":"Semin Pediatr Surg","first-page":"150969","article-title":"Infantile and congenital hemangiomas","volume":"29","author":"Olsen","year":"2020","unstructured":"Olsen GM, Nackers A, Drolet BA. Infantile and congenital hemangiomas. Semin Pediatr Surg. 2020;29(5):150969."},{"issue":"(15)","key":"i2331-348X-30-1-27-b29","series-title":"Eur Rev Med Pharmacol Sci","first-page":"4806","article-title":"Expression and correlation of MMP-9, VEGF, and p16 in infantile hemangioma","volume":"22","author":"Yin","year":"2018","unstructured":"Yin RR, Hao D, Chen P. Expression and correlation of MMP-9, VEGF, and p16 in infantile hemangioma. Eur Rev Med Pharmacol Sci.  2018;22(15):4806\u20134811."},{"issue":"(6)","key":"i2331-348X-30-1-27-b30","series-title":"Arch Dermatol","first-page":"718","article-title":"Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait","volume":"134","author":"Blei","year":"1998","unstructured":"Blei F, Walter J, Orlow SJ, Marchuk DA. Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait. Arch Dermatol.  1998;134(6):718\u2013722."},{"key":"i2331-348X-30-1-27-b31","series-title":"Microporous Mesoporous Mater","first-page":"110774","article-title":"Exploiting mesoporous silica nanoparticles as versatile drug carriers for several routes of administration","volume":"312","author":"S\u00e1bio","year":"2021","unstructured":"S\u00e1bio RM, Meneguin AB, Martins dos Santos A, et al. Exploiting mesoporous silica nanoparticles as versatile drug carriers for several routes of administration. Microporous Mesoporous Mater. 2021;(312):110774."},{"issue":"(6)","key":"i2331-348X-30-1-27-b32","series-title":"J Pediatr","first-page":"1021","article-title":"Gastrointestinal bleeding in infantile hemangioma: a complication of segmental, rather than multifocal, infantile hemangiomas","volume":"160","author":"Drolet","year":"2012","unstructured":"Drolet BA, Pope E, Juern AM, et al. Gastrointestinal bleeding in infantile hemangioma: a complication of segmental, rather than multifocal, infantile hemangiomas. J Pediatr. 2012;160(6):1021\u20131026.e3."},{"issue":"(20)","key":"i2331-348X-30-1-27-b33","series-title":"J Clin Med","first-page":"4631","article-title":"Infantile hemangiomas: an update on pathogenesis and treatment","volume":"10","author":"Kowalska","year":"2021","unstructured":"Kowalska M, D\u0119bek W, Matuszczak E. Infantile hemangiomas: an update on pathogenesis and treatment. J Clin Med. 2021;10(20):4631."},{"issue":"(4)","key":"i2331-348X-30-1-27-b34","series-title":"World J Pediatr","first-page":"377","article-title":"Risk factors for infantile hemangioma: a meta-analysis","volume":"16","author":"Ding","year":"2020","unstructured":"Ding Y, Zhang JZ, Yu SR, et al. Risk factors for infantile hemangioma: a meta-analysis. World J Pediatr. 2020;16(4):377\u2013384."},{"issue":"(4)","key":"i2331-348X-30-1-27-b35","series-title":"Br J Dermatol","first-page":"907","article-title":"Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies","volume":"170","author":"Munden","year":"2014","unstructured":"Munden A, Butschek R, Tom WL, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170(4):907\u2013913."},{"issue":"(17)","key":"i2331-348X-30-1-27-b36","series-title":"Ther Clin Risk Manag","first-page":"119","article-title":"Clinical features of segmental infantile hemangioma: a prospective study","volume":"27","author":"Qiu","year":"2021","unstructured":"Qiu T, Yang K, Dai S, et al. Clinical features of segmental infantile hemangioma: a prospective study. Ther Clin Risk Manag. 2021; Jan 27(17):119\u2013125."},{"issue":"(5)","key":"i2331-348X-30-1-27-b37","series-title":"Pediatr Dermatol","first-page":"383","article-title":"Infantile hemangiomas: current knowledge, future directions\u2014proceedings of a research workshop on infantile hemangiomas","volume":"22","author":"Frieden","year":"2005","unstructured":"Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions\u2014proceedings of a research workshop on infantile hemangiomas. Pediatr Dermatol. 2005;22(5):383\u2013406."},{"issue":"(1)","key":"i2331-348X-30-1-27-b38","series-title":"Otolaryngol Clin North Am","first-page":"77","article-title":"Infantile hemangiomas in the head and neck region","volume":"51","author":"Adams","year":"2018","unstructured":"Adams DM, Ricci KW. Infantile hemangiomas in the head and neck region. Otolaryngol Clin North Am. 2018;51(1):77\u201387."},{"issue":"(6)","key":"i2331-348X-30-1-27-b39","series-title":"J Am Acad Dermatol","first-page":"1395","article-title":"Infantile hemangioma\u2014Part 2: Management","volume":"85","author":"Sebaratnam","year":"2021","unstructured":"Sebaratnam DF, Rodr\u00edguez Bandera Al, Wong LCF, Wargon O. Infantile hemangioma\u2014Part 2: Management. J Am Acad Dermatol.  2021;85(6):1395\u20131404."},{"issue":"(3)","key":"i2331-348X-30-1-27-b40","series-title":"J Plast Rekonstruksi","first-page":"120","article-title":"Long term follow up of hemangioma on bilateral cleft lip","volume":"2","author":"Atmodiwirjo","year":"2013","unstructured":"Atmodiwirjo P, Lestari PA, Kesuma AD. Long term follow up of hemangioma on bilateral cleft lip. J Plast Rekonstruksi. 2013;2(3):120\u2013124."},{"issue":"(5)","key":"i2331-348X-30-1-27-b41","series-title":"Dermatology","first-page":"566","article-title":"Topical timolol maleate 0.5% for infantile hemangioma: Its effectiveness compared to ultrapotent topical corticosteroids: a single-center experience of 278 cases","volume":"232","author":"Danarti","year":"2017","unstructured":"Danarti R, Ariwibowo L, Radiono S, Budiyanto A. Topical timolol maleate 0.5% for infantile hemangioma: Its effectiveness compared to ultrapotent topical corticosteroids: a single-center experience of 278 cases. Dermatology. 2017;232(5):566\u2013571."},{"issue":"(3)","key":"i2331-348X-30-1-27-b42","series-title":"Pediatr Dermatol","first-page":"254","article-title":"Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream","volume":"22","author":"Hazen","year":"2005","unstructured":"Hazen PG, Carney JF, Engstrom CW, et al. Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr Dermatol.  2005;22(3):254\u2013256."},{"issue":"(24)","key":"i2331-348X-30-1-27-b43","series-title":"N Engl J Med","first-page":"2649","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, de la Roque ED, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649\u20132651."},{"issue":"(1)","key":"i2331-348X-30-1-27-b44","series-title":"Pediatr Dermatol","first-page":"28","article-title":"Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study","volume":"29","author":"Chakkittakandiyil","year":"2012","unstructured":"Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol. 2012;29(1):28\u201331."},{"issue":"(3)","key":"i2331-348X-30-1-27-b45","series-title":"Pediatrics","first-page":"e20160355","article-title":"Topical timolol maleate treatment of infantile hemangiomas","volume":"138","author":"P\u00fcttgen","year":"2016","unstructured":"P\u00fcttgen K, Lucky A, Adams D, et al. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics. 2016;138(3):e20160355."},{"issue":"(4)","key":"i2331-348X-30-1-27-b46","series-title":"J Pediatr Surg","first-page":"740","article-title":"Surgical resection of infantile hemangiomas following medical treatment with propranolol versus corticosteroids","volume":"54","author":"Polites","year":"2019","unstructured":"Polites SF, Watanabe M, Crafton T, et al. Surgical resection of infantile hemangiomas following medical treatment with propranolol versus corticosteroids. J Pediatr Surg. 2019;54(4):740\u2013743."},{"issue":"(2)","key":"i2331-348X-30-1-27-b47","series-title":"J Am Acad Dermatol","first-page":"281","article-title":"Ultrapotent topical corticosteroid treatment of hemangiomas of infancy","volume":"52","author":"Garzon","year":"2005","unstructured":"Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol. 2005;52(2):281\u2013286."},{"issue":"(5)","key":"i2331-348X-30-1-27-b48","series-title":"J Am Acad Dermatol","first-page":"1149","article-title":"Propranolol for the treatment of ulcerated infantile hemangiomas: a prospective study","volume":"86","author":"Ji","year":"2022","unstructured":"Ji Y, Yang K, Zhou J, et al. Propranolol for the treatment of ulcerated infantile hemangiomas: a prospective study. J Am Acad Dermatol. 2022;86(5):1149\u20131151."},{"issue":"(5)","key":"i2331-348X-30-1-27-b49","series-title":"Eur J Dermatol","first-page":"646","article-title":"Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial","volume":"23","author":"Zaher","year":"2013","unstructured":"Zaher H, Rasheed H, Esmat S, et al. Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial. Eur J Dermatol. 2013;23(5):646\u2013652."},{"issue":"(1)","key":"i2331-348X-30-1-27-b50","series-title":"Plast Reconstr Surg","first-page":"76","article-title":"Induced resolution of cavernous hemangiomas following prednisolone therapy","volume":"39","author":"Zarem","year":"1967","unstructured":"Zarem HA, Edgerton MT. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg. 1967;39(1):76\u201383."},{"issue":"1","key":"i2331-348X-30-1-27-b51","series-title":"Sci Rep","article-title":"Pharmacological therapies for infantile hemangiomas: a clinical study in 853 consecutive patients using a standard treatment algorithm","volume":"6)","author":"Zhang","year":"2016","unstructured":"Zhang L, Yuan WE, Zheng JW. Pharmacological therapies for infantile hemangiomas: a clinical study in 853 consecutive patients using a standard treatment algorithm. Sci Rep. 2016;(6):1\u20138."},{"issue":"(8)","key":"i2331-348X-30-1-27-b52","series-title":"Clin Exp Dermatol","first-page":"845","article-title":"Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study","volume":"38","author":"Qiu","year":"2013","unstructured":"Qiu Y, Ma G, Yang J, et al. Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study. Clin Exp Dermatol. 2013;38(8):845\u2013850."},{"key":"i2331-348X-30-1-27-b53","series-title":"Front Oncol","first-page":"3","article-title":"Topical application of 0.5% timolol maleate hydrogel for the treatment of superficial infantile hemangioma","volume":"7)","author":"Wu","year":"2017","unstructured":"Wu HW, Liu C, Wang X, et al. Topical application of 0.5% timolol maleate hydrogel for the treatment of superficial infantile hemangioma. Front Oncol. 2017;(7):3\u20138."},{"issue":"(11)","key":"i2331-348X-30-1-27-b54","series-title":"N Engl J Med","first-page":"1005","article-title":"Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells","volume":"362","author":"Greenberger","year":"2010","unstructured":"Greenberger S, Boscolo E, Adini I, et al. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med. 2010;362(11):1005\u20131013."},{"issue":"(1)","key":"i2331-348X-30-1-27-b55","series-title":"Nanomed Nanotech Biol Med","first-page":"127","article-title":"MRI molecular imaging using GLUT1 antibody-Fe3O4 nanoparticles in the hemangioma animal model for differentiating infantile hemangioma from vascular malformation","volume":"11","author":"Sohn","year":"2015","unstructured":"Sohn CH, Park SP, Choi SH, et al. MRI molecular imaging using GLUT1 antibody-Fe3O4 nanoparticles in the hemangioma animal model for differentiating infantile hemangioma from vascular malformation. Nanomed Nanotech Biol Med. 2015;11(1):127\u2013135."},{"key":"i2331-348X-30-1-27-b56","series-title":"Ann Med Surg","first-page":"91","article-title":"Integrated propranolol, methylprednisolone, and surgery in managing a rare case of infantile hemangioma with concurrent cleft lip and palate","author":"Dachlan","year":"2020","unstructured":"Dachlan I, Wahdini SI, Putri IL, et al. Integrated propranolol, methylprednisolone, and surgery in managing a rare case of infantile hemangioma with concurrent cleft lip and palate. Ann Med Surg. 2020;(56):91\u201394."},{"issue":"(4)","key":"i2331-348X-30-1-27-b57","series-title":"Curr Opin Otolaryngol Head Neck Surg","first-page":"286","article-title":"Current trends in medical management of infantile hemangioma","volume":"23","author":"Ames","year":"2015","unstructured":"Ames JA, Sykes JM. Current trends in medical management of infantile hemangioma. Curr Opin Otolaryngol Head Neck Surg. 2015;23(4):286\u2013291."},{"issue":"(3)","key":"i2331-348X-30-1-27-b58","series-title":"Plast Reconstr Surg","first-page":"467","article-title":"Intralesional corticosteroid therapy for infantile hemangiomas","volume":"83","author":"Sloan","year":"1989","unstructured":"Sloan GM, Reinisch JF, Nichter LS, et al. Intralesional corticosteroid therapy for infantile hemangiomas. Plast Reconstr Surg. 1989;83(3):467."},{"key":"i2331-348X-30-1-27-b59","series-title":"Gender and Dermatology","first-page":"215","article-title":"Infantile hemangioma","author":"Greenberger","year":"2018","unstructured":"Greenberger S. Infantile hemangioma. In: Ethel Tur, Maibach HI, eds. Gender and Dermatology. Cham: Springer International Publishing; 2018:215\u2013225."},{"key":"i2331-348X-30-1-27-b60","series-title":"Front Pharmacol","first-page":"1","article-title":"Update on treatment of infantile hemangiomas: what\u2019s new in the last five years?","volume":"13","author":"Macca","year":"2022","unstructured":"Macca L, Altavilla D, Di Bartolomeo L, et al. Update on treatment of infantile hemangiomas: what\u2019s new in the last five years? Front Pharmacol. 2022;(13):1\u20138."},{"issue":"(2)","key":"i2331-348X-30-1-27-b61","series-title":"Semin Plast Surg","first-page":"87","article-title":"Beta-blockers as therapy for infantile hemangiomas","volume":"28","author":"Nguyen","year":"2014","unstructured":"Nguyen HP, Pickrell BB, Wright TS. Beta-blockers as therapy for infantile hemangiomas. Semin Plast Surg.  2014;28(2):87\u201390."},{"issue":"(4)","key":"i2331-348X-30-1-27-b62","series-title":"Exp Ther Med","first-page":"594","article-title":"Propranolol treatment of infantile hemangioma endothelial cells: a molecular analysis","volume":"4","author":"Stiles","year":"2012","unstructured":"Stiles J, Amaya C, Pham R, et al. Propranolol treatment of infantile hemangioma endothelial cells: a molecular analysis. Exp Ther Med.  2012;4(4):594\u2013604."},{"issue":"(6)","key":"i2331-348X-30-1-27-b63","series-title":"JAMA Dermatol","first-page":"529","article-title":"Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial","volume":"153","author":"Kim","year":"2017","unstructured":"Kim KH, Choi TH, Choi Y, et al. Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial. JAMA Dermatol. 2017;153(6):529\u2013536."},{"issue":"(7)","key":"i2331-348X-30-1-27-b64","series-title":"J Pediatr Pharmacol Ther","first-page":"586","article-title":"Infantile hemangioma: a review of current pharmacotherapy treatment and practice pearls","volume":"25","author":"Tiemann","year":"2020","unstructured":"Tiemann L, Hein S. Infantile hemangioma: a review of current pharmacotherapy treatment and practice pearls. J Pediatr Pharmacol Ther.  2020;25(7):586\u2013599."},{"issue":"1","key":"i2331-348X-30-1-27-b65","series-title":"Front Surg","first-page":"10","article-title":"Biology of Infantile hemangioma","volume":"1","author":"Itinteang","year":"2014","unstructured":"Itinteang T, Withers AHJ, Davis PF, Tan ST. Biology of Infantile hemangioma. Front Surg. 2014;(1):1\u201310."},{"issue":"(12)","key":"i2331-348X-30-1-27-b66","series-title":"J Biomed Nanotechnol","first-page":"1694","article-title":"Promotion of propranolol delivery to hemangiomas by using anti-VEGFR antibody-conjugated poly(lactic-co-glycolic acid) nanoparticles","volume":"13","author":"Zhu","year":"2017","unstructured":"Zhu X, Guo X, Liu D, et al. Promotion of propranolol delivery to hemangiomas by using anti-VEGFR antibody-conjugated poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotechnol. 2017;13(12):1694\u20131705."},{"issue":"(11)","key":"i2331-348X-30-1-27-b67","series-title":"World J Surg Oncol","first-page":"1","article-title":"Urea immunoliposome inhibits human vascular endothelial cell proliferation for hemangioma treatment","author":"Wang","year":"2013","unstructured":"Wang Z, Li J, Xu X, et al. Urea immunoliposome inhibits human vascular endothelial cell proliferation for hemangioma treatment. World J Surg Oncol.  2013;(11):1\u20137."},{"key":"i2331-348X-30-1-27-b68","series-title":"J Am Acad Dermatol","first-page":"6","article-title":"Immunomodulatory and pharmacologic properties of imiquimod","volume":"43","author":"Sauder","year":"2000","unstructured":"Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43(1 pt II):6\u201311."},{"issue":"(5)","key":"i2331-348X-30-1-27-b69","series-title":"J Invest Dermatol","first-page":"1205","article-title":"Topically applied imiquimod inhibits vascular tumor growth in vivo","volume":"121","author":"Sidbury","year":"2003","unstructured":"Sidbury R, Neuschler N, Neuschler E, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol. 2003;121(5):1205\u20131209."},{"issue":"(2)","key":"i2331-348X-30-1-27-b70","series-title":"Pediatr Dermatol","first-page":"203","article-title":"A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma","volume":"26","author":"McCuaig","year":"2009","unstructured":"McCuaig CC, Dubois J, Powell J, et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol. 2009;26(2):203\u2013212."},{"issue":"(8)","key":"i2331-348X-30-1-27-b71","series-title":"Am J Clin Nutr","first-page":"1367","article-title":"Metabolism and recycling of urea in man","volume":"31","author":"Long","year":"1978","unstructured":"Long CL, Jeevanandam M, Kinney JM. Metabolism and recycling of urea in man. Am J Clin Nutr.  1978;31(8):1367\u20131382."},{"issue":"(1)","key":"i2331-348X-30-1-27-b72","series-title":"Oncol Rep","first-page":"109","article-title":"Significant inhibition of infantile hemangioma growth by sustained delivery of urea from liposomes-in-microspheres","volume":"39","author":"Zhu","year":"2018","unstructured":"Zhu X, Guo X, Liu D, et al. Significant inhibition of infantile hemangioma growth by sustained delivery of urea from liposomes-in-microspheres. Oncol Rep.  2018;39(1):109\u2013118."},{"issue":"(4)","key":"i2331-348X-30-1-27-b73","series-title":"J Cell Biochem","first-page":"\\5128","article-title":"Urea-modulated UT-B urea transporter internalization is clathrin- and caveolae-dependent in infantile hemangioma-derived vascular endothelial cells","volume":"120","author":"Xiao","year":"2019","unstructured":"Xiao L, Liu D, Zuo S, et al. Urea-modulated UT-B urea transporter internalization is clathrin- and caveolae-dependent in infantile hemangioma-derived vascular endothelial cells. J Cell Biochem.  2019;120(4):\\5128\u20135136."},{"issue":"(2)","key":"i2331-348X-30-1-27-b74","series-title":"J Gen Physiol","first-page":"127","article-title":"Water and nonelectrolyte permeability of lipid bilayer membranes","volume":"68","author":"Finkelstein","year":"1976","unstructured":"Finkelstein A. Water and nonelectrolyte permeability of lipid bilayer membranes. J Gen Physiol.  1976;68(2):127\u2013135."},{"issue":"(9)","key":"i2331-348X-30-1-27-b75","series-title":"Drug Des Devel Ther","first-page":"723","article-title":"Treatment of alarming head and neck infantile hemangiomas with interferon-\u03b12a: a clinical study in eleven consecutive patients","author":"Zhang","year":"2015","unstructured":"Zhang L, Zheng JW, Yuan WE. Treatment of alarming head and neck infantile hemangiomas with interferon-\u03b12a: a clinical study in eleven consecutive patients. Drug Des Devel Ther. 2015;(9):723\u2013727."},{"issue":"(2)","key":"i2331-348X-30-1-27-b76","series-title":"Acta Paediatr","first-page":"311","article-title":"Vincristine, an efficacious alternative for diffuse neonatal haemangiomatosis","volume":"99","author":"P\u00e9rez-Valle","year":"2010","unstructured":"P\u00e9rez-Valle S, Peinador M, Herraiz P, et al. Vincristine, an efficacious alternative for diffuse neonatal haemangiomatosis. Acta Paediatr. 2010;99(2):311\u2013315."},{"issue":"(5)","key":"i2331-348X-30-1-27-b77","series-title":"Surv Ophthalmol","first-page":"608","article-title":"Current treatment and management of infantile hemangiomas","volume":"64","author":"Satterfield","year":"2019","unstructured":"Satterfield KR, Chambers CB. Current treatment and management of infantile hemangiomas. Surv Ophthalmol. 2019;64(5):608\u2013618."},{"issue":"(1)","key":"i2331-348X-30-1-27-b78","series-title":"Mol Med Rep","first-page":"301","article-title":"Pingyangmycin stimulates apoptosis in human hemangioma-derived endothelial cells through activation of the p53 pathway","volume":"10","author":"Tu","year":"2014","unstructured":"Tu JB, Li QY, Jiang F, et al. Pingyangmycin stimulates apoptosis in human hemangioma-derived endothelial cells through activation of the p53 pathway. Mol Med Rep.  2014;10(1):301\u2013305."},{"issue":"(2)","key":"i2331-348X-30-1-27-b79","series-title":"Exp Ther Med","first-page":"473","article-title":"Proapoptotic effect and the mechanism of action of pingyangmycin on cavernous hemangiomas","volume":"7","author":"Huang","year":"2014","unstructured":"Huang Y, Li P, Xia S, et al. Proapoptotic effect and the mechanism of action of pingyangmycin on cavernous hemangiomas. Exp Ther Med.  2014;7(2):473\u2013477."},{"issue":"(9)","key":"i2331-348X-30-1-27-b80","series-title":"Bioconjug Chem","first-page":"2247","article-title":"Nanoparticle interactions with the tumor microenvironment","volume":"30","author":"Huai","year":"2019","unstructured":"Huai Y, Hossen MN, Wilhelm S, et al. Nanoparticle interactions with the tumor microenvironment. Bioconjug Chem.  2019;30(9):2247\u20132263."},{"key":"i2331-348X-30-1-27-b81","series-title":"Adv Drug Deliv Rev","first-page":"2","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","unstructured":"Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;(66):2\u201325."},{"issue":"(6976)","key":"i2331-348X-30-1-27-b82","series-title":"Nature","first-page":"695","article-title":"Cancer cells compress intratumour vessels","volume":"427","author":"Padera","year":"2004","unstructured":"Padera TP, Stoll BR, Tooredman JB, et al. Cancer cells compress intratumour vessels. Nature.  2004;427(6976):695."},{"key":"i2331-348X-30-1-27-b83","series-title":"Nat Rev Clin Oncol","first-page":"653","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","unstructured":"Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;(7):653\u2013664."},{"issue":"(9)","key":"i2331-348X-30-1-27-b84","series-title":"Int J Mol Sci","first-page":"3358","article-title":"Recent advances in porphyrin-based inorganic nanoparticles for cancer treatment","volume":"21","author":"Montaseri","year":"2020","unstructured":"Montaseri H, Kruger CA, Abrahamse H. Recent advances in porphyrin-based inorganic nanoparticles for cancer treatment. Int J Mol Sci. 2020;21(9):3358."},{"issue":"(2)","key":"i2331-348X-30-1-27-b85","series-title":"Plast Reconstr Surg","first-page":"410","article-title":"Developing a nanoparticle-delivered high-efficacy treatment for infantile hemangiomas using a mouse hemangioendothelioma model","volume":"138","author":"Orbay","year":"2016","unstructured":"Orbay H, Li Y, Xiao W, et al. Developing a nanoparticle-delivered high-efficacy treatment for infantile hemangiomas using a mouse hemangioendothelioma model. Plast Reconstr Surg. 2016;138(2):410\u2013417."},{"issue":"(6)","key":"i2331-348X-30-1-27-b86","series-title":"Deliv Syst Handb Pers Care Cosmet Prod","first-page":"101","article-title":"Delivery system design in topically applied formulations: an overview","volume":"8","author":"Dayan","year":"2005","unstructured":"Dayan N. Delivery system design in topically applied formulations: an overview. Deliv Syst Handb Pers Care Cosmet Prod. 2005;8(6):101\u2013118."},{"key":"i2331-348X-30-1-27-b87","series-title":"Contri R-V, Fiel LA, Pohlmann AR, et al. Nanocosmet Nanomed","article-title":"Transport of substances and nanoparticles across the skin and in vitro models to evaluate skin permeation and\/or penetration","author":"Contri","unstructured":"Contri RV, Fiel LA, Pohlmann AR, et al. Transport of substances and nanoparticles across the skin and in vitro models to evaluate skin permeation and\/or penetration. In: Contri R-V, Fiel LA, Pohlmann AR, et al. Nanocosmet Nanomed. Springer-Verlag Berlin Heidelber;2011:p3\u201335."},{"issue":"(1)","key":"i2331-348X-30-1-27-b88","series-title":"Biomed Dermatol","first-page":"1","article-title":"Transdermal delivery systems in cosmetics","volume":"4","author":"Kim","year":"2020","unstructured":"Kim B, Cho H-E, Moon SH, et al. Transdermal delivery systems in cosmetics. Biomed Dermatol. 2020;4(1):1\u201312."},{"issue":"(3)","key":"i2331-348X-30-1-27-b89","series-title":"Clin Dermatol","first-page":"271","article-title":"Newborn infant skin: physiology, development, and care","volume":"33","author":"Visscher","year":"2015","unstructured":"Visscher MO, Adam R, Brink S, Odio M. Newborn infant skin: physiology, development, and care. Clin Dermatol. 2015;33(3):271\u2013280."},{"key":"i2331-348X-30-1-27-b90","series-title":"Dermatol Res Pract","first-page":"198789","article-title":"The infant skin barrier: can we preserve, protect, and enhance the barrier?","volume":"2012","author":"Telofski","year":"2012","unstructured":"Telofski LS, Morello AP, Mack Correa MC, Stamatas GN. The infant skin barrier: can we preserve, protect, and enhance the barrier? Dermatol Res Pract.  2012;2012:198789."},{"issue":"(1)","key":"i2331-348X-30-1-27-b91","series-title":"Int J Cosmet Sci","first-page":"17","article-title":"Infant skin physiology and development during the first years of life: a review of recent findings based on in vivo studies","volume":"33","author":"Stamatas","year":"2011","unstructured":"Stamatas GN, Nikolovski J, MacK MC, Kollias N. Infant skin physiology and development during the first years of life: a review of recent findings based on in vivo studies. Int J Cosmet Sci. 2011;33(1):17\u201324."},{"issue":"(10)","key":"i2331-348X-30-1-27-b92","series-title":"J Invest Dermatol","first-page":"2224","article-title":"Multiphoton microscopy for the investigation of dermal penetration of nanoparticle-borne drugs","volume":"126","author":"Stracke","year":"2006","unstructured":"Stracke F, Weiss B, Lehr CM, et al. Multiphoton microscopy for the investigation of dermal penetration of nanoparticle-borne drugs. J Invest Dermatol. 2006;126(10):2224\u20132233."},{"issue":"(3)","key":"i2331-348X-30-1-27-b93","series-title":"Sci Pharm","first-page":"17","article-title":"Nanoemulsion: a review on mechanisms for the transdermal delivery of hydrophobic and hydrophilic drugs","volume":"87","author":"Shaker","year":"2019","unstructured":"Shaker DS, Ishak RAH, Ghoneim A, Elhuoni MA. Nanoemulsion: a review on mechanisms for the transdermal delivery of hydrophobic and hydrophilic drugs. Sci Pharm. 2019;87(3):17."},{"issue":"(10)","key":"i2331-348X-30-1-27-b94","series-title":"Am J Appl Sci","first-page":"1270","article-title":"Utilization of gum Arabic for industries and human health","volume":"10","author":"Dauqan","year":"2013","unstructured":"Dauqan E, Abdullah A. Utilization of gum Arabic for industries and human health. Am J Appl Sci.  2013;10(10):1270\u20131279."},{"issue":"(1)","key":"i2331-348X-30-1-27-b95","series-title":"Int J Polym Sci","first-page":"7697031","article-title":"Alginate: current use and future perspectives in pharmaceutical and biomedical applications","volume":"2016","author":"Szekalska","year":"2016","unstructured":"Szekalska M, Puci\u0142owska A, Szyma\u0144ska E, et al. Alginate: current use and future perspectives in pharmaceutical and biomedical applications. Int J Polym Sci.  2016;2016(1):7697031."},{"issue":"(3)","key":"i2331-348X-30-1-27-b96","series-title":"J Pharm Sci","first-page":"1337","article-title":"Development of lecithin\/chitosan nanoparticles for promoting topical delivery of propranolol hydrochloride: design, optimization and in-vivo evaluation","volume":"110","author":"Khalil","year":"2021","unstructured":"Khalil RM, El Arini SK, AbouSamra MM, et al. Development of lecithin\/chitosan nanoparticles for promoting topical delivery of propranolol hydrochloride: design, optimization and in-vivo evaluation. J Pharm Sci. 2021;110(3):1337\u20131348."},{"issue":"(2)","key":"i2331-348X-30-1-27-b97","series-title":"Polymers (Basel)","first-page":"213","article-title":"Cosmetics and cosmeceutical applications of chitin, chitosan and their derivatives","volume":"10","author":"Aranaz","year":"2018","unstructured":"Aranaz I, Acosta N, Civera C, et al. Cosmetics and cosmeceutical applications of chitin, chitosan and their derivatives. Polymers (Basel).  2018;10(2):213."},{"issue":"(2)","key":"i2331-348X-30-1-27-b98","series-title":"Adv Pharm Bull","first-page":"195","article-title":"Current advances in chitosan nanoparticles based drug delivery and targeting","volume":"9","author":"Garg","year":"2019","unstructured":"Garg U, Chauhan S, Nagaich U, Jain N. Current advances in chitosan nanoparticles based drug delivery and targeting. Adv Pharm Bull. 2019;9(2):195\u2013204."},{"issue":"(11)","key":"i2331-348X-30-1-27-b99","series-title":"Mar Drugs","first-page":"583","article-title":"Carrageenan: drug delivery systems and other biomedical applications","volume":"18","author":"Pacheco-Quito","year":"2020","unstructured":"Pacheco-Quito EM, Ruiz-Caro R, Veiga MD. Carrageenan: drug delivery systems and other biomedical applications. Mar Drugs. 2020;18(11):583."},{"issue":"(4)","key":"i2331-348X-30-1-27-b100","series-title":"Adv Pharm Bull","first-page":"566","article-title":"Eco-friendly greener synthesis of nanoparticles","volume":"10","author":"Bhardwaj","year":"2020","unstructured":"Bhardwaj B, Singh P, Kumar A, et al. Eco-friendly greener synthesis of nanoparticles. Adv Pharm Bull. 2020;10(4):566\u2013576."},{"issue":"(2)","key":"i2331-348X-30-1-27-b101","series-title":"Al Azhar Med J","first-page":"363","article-title":"Comparative study between systemic and topical propranolol in treatment of infantile hemangiomas","volume":"46","author":"El-Sayaad","year":"2017","unstructured":"El-Sayaad IM, Shahin MM, Abdelmonem SAE, et al. Comparative study between systemic and topical propranolol in treatment of infantile hemangiomas. Al Azhar Med J. 2017;46(2):363\u2013372."},{"issue":"(1)","key":"i2331-348X-30-1-27-b102","series-title":"J Craniofac Surg","first-page":"56","article-title":"Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions","volume":"27","author":"Li","year":"2016","unstructured":"Li G, Xu DP, Tong S, et al. Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions. J Craniofac Surg. 2016;27(1):56\u201360."},{"issue":"(3)","key":"i2331-348X-30-1-27-b103","series-title":"Pediatr Dermatol","first-page":"283","article-title":"Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas","volume":"36","author":"Mannschreck","year":"2019","unstructured":"Mannschreck DB, Huang AH, Lie E, et al. Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2019;36(3):283\u2013289."},{"issue":"(4)","key":"i2331-348X-30-1-27-b104","series-title":"J Vasc Anomalies","first-page":"e048","article-title":"Evaluating the use of atenolol for the treatment of infantil hemangioma","volume":"3","author":"Pathman","year":"2022","unstructured":"Pathman L, Simpson J, Penington AJ, et al. Evaluating the use of atenolol for the treatment of infantil hemangioma. J Vasc Anomalies. 2022;3(4):e048."},{"issue":"(1)","key":"i2331-348X-30-1-27-b105","series-title":"JAMA Pediatr","first-page":"34","article-title":"Noninferiority and safety of nadolol vs propranolol in infants with infantile hemangioma: a randomized clinical trial","volume":"176","author":"Pope","year":"2022","unstructured":"Pope E, Lara-Corrales I, Sibbald C, et al. Noninferiority and safety of nadolol vs propranolol in infants with infantile hemangioma: a randomized clinical trial. JAMA Pediatr. 2022;176(1):34\u201341."},{"key":"i2331-348X-30-1-27-b106","series-title":"Adv Drug Deliv Rev","first-page":"87","article-title":"Nanoparticles for topical drug delivery: potential for skin cancer treatment","volume":"153","author":"Krishnan","year":"2020","unstructured":"Krishnan V, Mitragotri S. Nanoparticles for topical drug delivery: potential for skin cancer treatment. Adv Drug Deliv Rev. 2020;153:87\u2013108."},{"issue":"(2)","key":"i2331-348X-30-1-27-b107","series-title":"Int J Pharm","first-page":"123","article-title":"Liposomes in drug delivery: progress and limitations","volume":"154","author":"Sharma","year":"1997","unstructured":"Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997;154(2):123\u2013140."},{"key":"i2331-348X-30-1-27-b108","series-title":"Int J Pharm","first-page":"120130","article-title":"Thiolated and PEGylated silica nanoparticle delivery to hair follicles","volume":"593","author":"Al Mahrooqi","year":"2021","unstructured":"Al Mahrooqi JH, Khutoryanskiy VV, Williams AC. Thiolated and PEGylated silica nanoparticle delivery to hair follicles. Int J Pharm. 2021;593:120130."},{"issue":"(9)","key":"i2331-348X-30-1-27-b109","series-title":"Proc Natl Acad Sci U S A","first-page":"4194","article-title":"Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation","volume":"75","author":"Szoka","year":"1978","unstructured":"Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A.  1978;75(9):4194\u20134198."},{"issue":"(9)","key":"i2331-348X-30-1-27-b110","series-title":"Adv Healthc Mater","first-page":"1","article-title":"Propranolol-loaded mesoporous silica nanoparticles for treatment of infantile hemangiomas","volume":"8","author":"Wu","year":"2019","unstructured":"Wu H, Wang X, Zheng J, et al. Propranolol-loaded mesoporous silica nanoparticles for treatment of infantile hemangiomas. Adv Healthc Mater. 2019;8(9):1\u201312."},{"issue":"(6)","key":"i2331-348X-30-1-27-b111","series-title":"Oncol Rep","first-page":"3099","article-title":"Propranolol represses infantile hemangioma cell growth through the \u03b22-adrenergic receptor in a HIF-1\u03b1-dependent manner","volume":"33","author":"Li","year":"2015","unstructured":"Li P, Guo Z, Gao Y, Pan W. Propranolol represses infantile hemangioma cell growth through the \u03b22-adrenergic receptor in a HIF-1\u03b1-dependent manner. Oncol Rep. 2015;33(6):3099\u20133107."},{"issue":"(5)","key":"i2331-348X-30-1-27-b112","series-title":"Nanomedicine","first-page":"1109","article-title":"A novel topical nano-propranolol for treatment of infantile hemangiomas","volume":"11","author":"Chen","year":"2015","unstructured":"Chen ZG, Zheng JW, Yuan ML, et al. A novel topical nano-propranolol for treatment of infantile hemangiomas. Nanomedicine.  2015;11(5):1109\u20131115."},{"key":"i2331-348X-30-1-27-b113","series-title":"Design of Nanostructures for Theranostics Applications","first-page":"437","article-title":"Mesoporous silica nanoparticles as drug delivery systems against melanoma","author":"Zieli\u0144ska","year":"2018","unstructured":"Zieli\u0144ska A, Pereira I, Antunes S, et al.  Mesoporous silica nanoparticles as drug delivery systems against melanoma. In: Grumezescu AM, eds. Design of Nanostructures for Theranostics Applications. William Andrew Publishing; 2018:437\u2013466."},{"key":"i2331-348X-30-1-27-b114","series-title":"Colloids Surf B Biointerfaces","first-page":"530","article-title":"Silica nanoparticles as sources of silicic acid favoring wound healing in vitro","volume":"155","author":"Quignard","year":"2017","unstructured":"Quignard S, Coradin T, Powell JJ, Jugdaohsingh R. Silica nanoparticles as sources of silicic acid favoring wound healing in vitro. Colloids Surf B Biointerfaces. 2017;155:530\u2013537."},{"issue":"(1)","key":"i2331-348X-30-1-27-b115","series-title":"J Porous Mater","first-page":"217","article-title":"Chitosan oligosaccharide coated mesoporous silica nanoparticles for pH-stimuli responsive drug delivery applications","volume":"26","author":"Moorthy","year":"2019","unstructured":"Moorthy MS, Hoang G, Manivasagan P, et al. Chitosan oligosaccharide coated mesoporous silica nanoparticles for pH-stimuli responsive drug delivery applications. J Porous Mater.  2019;26(1):217\u2013226."},{"issue":"(1\u20132)","key":"i2331-348X-30-1-27-b116","series-title":"Int J Pharm","first-page":"325","article-title":"Mesoporous silica nanoparticles for enhanced lidocaine skin delivery","volume":"550","author":"Nafisi","year":"2018","unstructured":"Nafisi S, Samadi N, Houshiar M, Maibach HI. Mesoporous silica nanoparticles for enhanced lidocaine skin delivery. Int J Pharm. 2018;550(1\u20132):325\u2013332."},{"key":"i2331-348X-30-1-27-b117","series-title":"Int J Pharm","first-page":"120609","article-title":"Can mesoporous nanoparticles promote bioavailability of topical pharmaceutics?","volume":"602","author":"Valetti","year":"2021","unstructured":"Valetti S, Thomsen H, Wankar J, et al. Can mesoporous nanoparticles promote bioavailability of topical pharmaceutics? Int J Pharm. 2021;602:120609."},{"issue":"(1)","key":"i2331-348X-30-1-27-b118","series-title":"Adv Pharm Bull","first-page":"31","article-title":"The effect of particle size on the deposition of solid lipid nanoparticles in different skin layers: a histological study","volume":"6","author":"Adib","year":"2016","unstructured":"Adib ZM, Ghanbarzadeh S, Kouhsoltani M, et al. The effect of particle size on the deposition of solid lipid nanoparticles in different skin layers: a histological study. Adv Pharm Bull. 2016;6(1):31\u201336."},{"key":"i2331-348X-30-1-27-b119","series-title":"Int J Pharm","first-page":"49","article-title":"Biocompatible nanoparticles and vesicular systems in transdermal drug delivery for various skin diseases","volume":"555","author":"Carter","year":"2019","unstructured":"Carter P, Narasimhan B, Wang Q. Biocompatible nanoparticles and vesicular systems in transdermal drug delivery for various skin diseases. Int J Pharm. 2019;555:49\u201362."},{"key":"i2331-348X-30-1-27-b120","series-title":"Int J Nanomedicine","first-page":"2827","article-title":"Development and characterization of a nanoemulsion containing propranolol for topical delivery","volume":"13","author":"Zanela da Silva Marques","year":"2018","unstructured":"Zanela da Silva Marques T, Santos-Oliveira R, De Siqueira LB de O, et al. Development and characterization of a nanoemulsion containing propranolol for topical delivery. Int J Nanomedicine. 2018;13:2827\u20132837."},{"issue":"(1\u20132)","key":"i2331-348X-30-1-27-b121","series-title":"Int J Pharm","first-page":"132","article-title":"Development of SLNs from natural lipids: application to topical delivery of tretinoin","volume":"363","author":"Mandawgade","year":"2008","unstructured":"Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm. 2008;363(1\u20132):132\u2013138."},{"issue":"(2)","key":"i2331-348X-30-1-27-b122","series-title":"Pharm Dev Technol","first-page":"164","article-title":"All-trans retinoic acid-loaded lipid nanoparticles as a transdermal drug delivery carrier","volume":"19","author":"Charoenputtakhun","year":"2014","unstructured":"Charoenputtakhun P, Opanasopit P, Rojanarata T, Ngawhirunpat T. All-trans retinoic acid-loaded lipid nanoparticles as a transdermal drug delivery carrier. Pharm Dev Technol. 2014;19(2):164\u2013172."},{"key":"i2331-348X-30-1-27-b123","series-title":"J Drug Deliv Sci Technol","first-page":"104099","article-title":"Propranolol-loaded nanostructured lipid carriers for topical treatment of infantile hemangioma","volume":"80","author":"Rocha","year":"2023","unstructured":"Rocha JL, Pires FQ, Gross IP, et al. Propranolol-loaded nanostructured lipid carriers for topical treatment of infantile hemangioma. J Drug Deliv Sci Technol. 2023;80:104099."},{"issue":"(7)","key":"i2331-348X-30-1-27-b124","series-title":"AAPS PharmSciTech","first-page":"266","article-title":"Preparation and evaluation of cubic nanoparticles for improved transdermal delivery of propranolol hydrochloride","volume":"21","author":"Zeng","year":"2020","unstructured":"Zeng L, Tao C, Liu Z, et al. Preparation and evaluation of cubic nanoparticles for improved transdermal delivery of propranolol hydrochloride. AAPS PharmSciTech. 2020;21(7):266."},{"key":"i2331-348X-30-1-27-b125","series-title":"J Drug Deliv Sci Technol","first-page":"102235","article-title":"Enhanced skin delivery of propranolol HCl using nonionic surfactant-based vesicles for topical treatment of infantile hemangioma","volume":"61","author":"Abdel-Aziz","year":"2021","unstructured":"Abdel-Aziz RT, Aly UF, Mady FM. Enhanced skin delivery of propranolol HCl using nonionic surfactant-based vesicles for topical treatment of infantile hemangioma. J Drug Deliv Sci Technol. 2021;61:102235."},{"issue":"(1)","key":"i2331-348X-30-1-27-b126","series-title":"J Control Release","first-page":"1","article-title":"Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery","volume":"30","author":"Schreier","year":"1994","unstructured":"Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release. 1994;30(1):1\u201315."},{"issue":"(5)","key":"i2331-348X-30-1-27-b127","series-title":"Skin Pharmacol Physiol","first-page":"209","article-title":"Liposomes and niosomes as topical drug delivery systems","volume":"18","author":"Choi","year":"2005","unstructured":"Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol. 2005;18(5):209\u2013219."},{"issue":"(4)","key":"i2331-348X-30-1-27-b128","series-title":"Adv Pharm Bull","first-page":"447","article-title":"A review of molecular mechanisms involved in toxicity of nanoparticles","volume":"5","author":"Fard","year":"2015","unstructured":"Fard JK, Jafari S, Eghbal MA. A review of molecular mechanisms involved in toxicity of nanoparticles. Adv Pharm Bull. 2015;5(4):447\u2013454."},{"key":"i2331-348X-30-1-27-b129","series-title":"Biomed Pharmacother","first-page":"875","article-title":"Inhibition of hemangioma growth using polymer\u2013lipid hybrid nanoparticles for delivery of rapamycin","volume":"95","author":"Li","year":"2017","unstructured":"Li H, Teng Y, Sun J, Liu J. Inhibition of hemangioma growth using polymer\u2013lipid hybrid nanoparticles for delivery of rapamycin. Biomed Pharmacother. 2017;95:875\u2013884."},{"issue":"(1)","key":"i2331-348X-30-1-27-b130","series-title":"Recent Patents Nanomed","first-page":"52","article-title":"Polymers and biopolymers as drug delivery systems in nanomedicine","volume":"2","author":"Goudoulas","year":"2012","unstructured":"Goudoulas T. Polymers and biopolymers as drug delivery systems in nanomedicine. Recent Patents Nanomed. 2012;2(1):52\u201361."},{"key":"i2331-348X-30-1-27-b131","series-title":"Int J Nanomedicine","first-page":"6963","article-title":"Delivery of sodium morrhuate to hemangioma endothelial cells using immunoliposomes conjugated with anti-VEGFR2\/KDR antibody","volume":"12","author":"Li","year":"2017","unstructured":"Li X, Ren X, Liang J, et al. Delivery of sodium morrhuate to hemangioma endothelial cells using immunoliposomes conjugated with anti-VEGFR2\/KDR antibody. Int J Nanomedicine. 2017;12:6963\u20136972."},{"issue":"(2)","key":"i2331-348X-30-1-27-b132","series-title":"Shanghai Kou Qiang Yi Xue","first-page":"71","article-title":"Clinical summary of relatively large dose of sodium morrhuate injection for the treatment of maxillofacial cavernous hemangionma: a report of 764 cases [in Chinese]","volume":"5","author":"Shou","year":"1996","unstructured":"Shou BQ, Yang Z, Meng ZY, et al. Clinical summary of relatively large dose of sodium morrhuate injection for the treatment of maxillofacial cavernous hemangionma: a report of 764 cases [in Chinese]. Shanghai Kou Qiang Yi Xue.  1996;5(2):71\u201373."},{"issue":"(6)","key":"i2331-348X-30-1-27-b133","series-title":"Int J Mol Med","first-page":"3586","article-title":"Enhanced rapamycin delivery to hemangiomas by lipid polymer nanoparticles coupled with anti-VEGFR antibody","volume":"41","author":"Li","year":"2018","unstructured":"Li H, Teng Y, Xu X, Liu J. Enhanced rapamycin delivery to hemangiomas by lipid polymer nanoparticles coupled with anti-VEGFR antibody. Int J Mol Med. 2018;41(6):3586\u20133596."},{"issue":"(21)","key":"i2331-348X-30-1-27-b134","series-title":"Nanomedicine","first-page":"2611","article-title":"PLGA nanoparticles with cd 133 aptamers for targeted delivery and sustained release of propranolol to hemangioma","volume":"12","author":"Guo","year":"2017","unstructured":"Guo X, Zhu X, Gao J, et al. PLGA nanoparticles with cd 133 aptamers for targeted delivery and sustained release of propranolol to hemangioma. Nanomedicine.  2017;12(21):2611\u20132624."},{"key":"i2331-348X-30-1-27-b135","series-title":"Biomed Pharmacother","first-page":"108823","article-title":"The sustained and targeted treatment of hemangiomas by propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres","volume":"114","author":"Guo","year":"2019","unstructured":"Guo X, Dong C, Liu Q, et al. The sustained and targeted treatment of hemangiomas by propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres. Biomed Pharmacother. 2019;114:108823."},{"key":"i2331-348X-30-1-27-b136","series-title":"Eur J Pharm Sci","first-page":"105765","article-title":"Chitosan nanoparticles for enhancing drugs and cosmetic components penetration through the skin","volume":"160","author":"Ta","year":"2021","unstructured":"Ta Q, Ting J, Harwood S, et al. Chitosan nanoparticles for enhancing drugs and cosmetic components penetration through the skin. Eur J Pharm Sci. 2021;160:105765."},{"issue":"(6)","key":"i2331-348X-30-1-27-b137","series-title":"China J Oral Maxilofac Surg","first-page":"445","article-title":"The effect of lipo-sodium morrhuate on human hemangioma endothelial cells","volume":"5","author":"Tu","year":"2007","unstructured":"Tu JB, Wang ZH, Song Y, et al. The effect of lipo-sodium morrhuate on human hemangioma endothelial cells. China J Oral Maxilofac Surg. 2007;5(6):445\u2013450."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/1\/article-p27.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/1\/article-p27.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/1\/article-p27.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T14:25:25Z","timestamp":1745245525000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/1\/article-p27.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":137,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-30.1.27","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}